Biopharmaceuticals at the forefront of knowledge

Eight Russian scientists received a prize from the pharmaceutical businessInfox.ru

At the IV All-Russian Science Festival, the organizers of the competition of scientific papers in the field of chemistry, biology and pharmacy "Vanguard of Knowledge" awarded the authors of the best scientific papers in the field of cardiology and oncology. The participants of the event discussed the possibilities of public-private partnership for the innovative development of Russian science.

Four research papers in the field of oncology and four in the field of cardiology were recognized by the expert jury as the most promising from a scientific point of view. Their authors received a cash prize from the organizers, as well as the opportunity to continue their research in partnership with Russian development institutes.

The competition "Vanguard of Knowledge" was organized by the AstraZeneca biopharmaceutical company with the assistance of the Skolkovo Foundation, the Russian Venture Company and the Rusnano Corporation. Its purpose is to promote the rise of Russian science and increase the motivation of scientists to carry out research in Russia.

The winners were awarded within the framework of the interactive discussion "Public-Private Partnership: Business and Science", which was attended by representatives of the Russian scientific community, government, business, as well as Russian development institutes – Skolkovo, RVC and Rusnano. The participants of the discussion discussed various models of effective public-private partnerships that stimulate the innovative development of Russian science. As examples, the research areas touched upon in the works of the winners were taken – bioinformatics, the use of stem cells, personalized medicine and systems for targeted delivery of therapeutic agents.

The competition "Vanguard of Knowledge" has been held by AstraZeneca for more than ten years. It is successfully held in Japan, China, South Korea. In Russia, the competition is being held this year for the first time.

Laureates

The organizers selected 8 best works from more than 80 submitted for the competition.

The award in the cardiology category was received by:

Alexander Tyukavin, MD, Professor, Head of the Department of Physiology and Pathology of the St. Petersburg State Chemical and Pharmaceutical Academy, Head of the Institute of Systemic Circulation of the Institute of Experimental Medicine of the Almazov Federal Research Center for Heart, Blood and Endocrinology.

Project: "Study of the mechanisms of targeted migration of stem cells into damaged tissues to assess the prospects of creating a new class of drugs that restore the structure and function of the heart after myocardial infarction."

Depending on the results, a genetic engineering or chemical technology of drugs simulating products of programmed cell death for various tissues will be created.

Vladimir Poryvaev, Professor, Doctor of Biological Sciences, Candidate of Physical and Mathematical Sciences, Head of the Department of the Russian Academy of Medical Sciences Research Institute of Biomedical Chemistry named after V.N. Orekhovich RAMS (IBMH RAMS).

Project: "Identification of low molecular weight organic compounds potentially suitable for the treatment of atherosclerosis by computer screening in databases of available chemicals."

The results of the study will help in the search for more effective and safe anti-atherosclerotic substances, the introduction into medical practice of new drugs for the treatment of atherosclerosis.

Konstantin Dergilev, Candidate of Medical Sciences, Junior Researcher at the Laboratory of Angiogenesis of the Research Institute of Experimental Cardiology of the Federal State University "Russian Cardiological Research and Production Complex" of the Ministry of Health and Social Development of the Russian Federation.

Project: "Characterization of c-kit positive resident myocardial stem cells in patients with coronary heart disease".

The results of the study can form the basis for the development of methods for stimulating endogenous mechanisms of myocardial regeneration.

Alexander Dmitriev, Candidate of Biological Sciences, Researcher at the V.N. Orekhovich Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences.

Project: "Development of methods for computer prediction of drug-drug interaction and biotransformation of drugs for the treatment of cardiovascular diseases".

The created web service will be in demand by researchers developing new medicinal substances. It will simplify the process and reduce the cost of developing new drugs for the treatment of cardiovascular diseases.

The award in the oncology category was received by:

Ekaterina Ignatova, post-graduate student of the Department of Clinical Pharmacology and Chemotherapy of the Blokhin Russian Cancer Research Center.

Project: "Determination of BRCA1 dysfunction in patients with early sporadic triple negative variant of breast cancer receiving neoadjuvant chemotherapy with the inclusion of platinum preparations".

The study will identify a group of patients who are highly sensitive to platinum-containing chemotherapy regimens. Thus, the survival rate of these patients will increase.

Natalia Petrova, Candidate of Chemical Sciences, Junior Researcher at the Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk.

Project: "Cholesterol-containing anti-MDR1 small interfering RNAs: accumulation in cells and biological activity".

As a result of the research, a drug based on chemically modified small interfering RNAs will be obtained. It will become a prototype of a drug to overcome multidrug resistance, designed to increase the effectiveness of chemotherapy in the treatment of oncological diseases.

Elena Svirshchevskaya, Candidate of Biological Sciences, Senior Researcher at the M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences (IBH).

Project: "Optimization of nanoscale small interfering RNA delivery systems for breast tumor therapy (mouse model)".

The data obtained can be used in the creation of drugs for the treatment of cancer based on known drugs. This will reduce the overall toxicity to normal tissues, which is now the main side effect of antitumor therapy.

Vladimir Shamanin, Candidate of Biological Sciences, Leading researcher of BioLink LLC (Novosibirsk region, Berdsk).

Project: "Identification of somatic mutations of the EGFR gene in the blood of patients with lung cancer to predict the response to gefitinib and erlotinib".

As a result, new laboratory tests and reagent kits for molecular diagnostics in oncology will be created.

Portal "Eternal youth" http://vechnayamolodost.ru 10.10.2011